Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.52 USD
+0.01 (2.94%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.52 0.00 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 301 - 320 ( 321 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Studies of SB-728-T for HIV To Be Featured at the Interscience Conference on Antimicrobial Agents and Chemotherapy
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials: Cash Runway Through Three Major Clinical Catalysts in H2:11.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Zinc Finger Protein Clinical Applications Highlighted At The American Society Of Gene And Cell Therapy (ASGCT) Conference.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Financing Strengthens Balance Sheet Ahead of Potential Therapeutic Partnership Negotiations
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Collaboration Uses Zinc Finger Protein Technology To Develop Treatments for Huntington''s Disease
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CROI 2011 Presentations Provide Mechanistic Proof-of-Concept and Highlight the Direction of the ZFN Approach for HIV/AIDS.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 23
Provider: WEDBUSH SECURITIES INC.
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials Were a Non-event. We See Important Clinical Milestones As Value Drivers For The Next Twelve Months. Raising Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 2010 Major Value Drivers in Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials Were Uneventful. We See Important Clinical Milestones As Value Drivers For The Next Twelve Months.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences: Biopharmaceuticals / Biotechnology.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials A Non-Event; Company Continues to Execute While Managing Cash Burn and We See Important Clinical Milestones in 2010
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials Uneventful; However, We See Sufficient Cash Through Important Clinical Milestones in 2010. Fair Value Moves to $12.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Phase I Data of SB-728-T for HIV Shows Promise But Still Early.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L